Fresh Off IPO, A Director Buys $474,000 of Parabilis Medicines Stock. Is PBLS a Buy?
Parabilis Medicines, a Cambridge, Massachusetts, biotech innovator in oncology, reported a notable insider buy amid ongoing development of cancer therapies.
Fresh Off IPO, A Director Buys $474,000 of Parabilis Medicines Stock. Is PBLS a Buy?
Overview
Just a few days after a well-received initial public offering, a director of drug developer Parabilis Medicines (NASDAQ:PBLS) bought shares in the open market.
Director Alan Sebulsky disclosed the purchase of 17,500 shares in multiple open-market transactions on June 12 and June 15, 2026, for a total consideration of approximately $474,000, according to the SEC Form 4 filing.
Details
Transaction value based on SEC Form 4 weighted average purchase price ($27.06); post-transaction value based on June 18, 2026 market close ($25.85).
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.
